The FDA commissioner search remains unresolved following Marty Makary’s May 2026 resignation, leaving Kyle Diamantas as acting commissioner with a record of advancing food safety and nutrition priorities. White House vetting of finalists including Heidi Overton, Jeffrey Vacirca, and Stephen Ferrara continued into July 2026, yet no nomination has emerged by mid-August. This delay elevates the probability of no announcement before December 31 while sustaining support for Diamantas and lower odds for experienced figures such as Brett Giroir, Sara Brenner, Stephen Hahn, and Grace Graham. Senate confirmation dynamics, the preference for candidates with medical or regulatory backgrounds, and midterm-year timing all contribute to the tight distribution of implied probabilities among traders assessing the next permanent nominee.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedKyle Diamantas 13%
Brett Giroir 8.2%
Sara Brenner 7.2%
Stephen Hahn 6.2%
$18,953 Vol.
$18,953 Vol.
Dec 31, 2026
Kyle Diamantas
25%
Stephen Hahn
6%
Brett Giroir
8%
Grace Graham
4%
Sara Brenner
7%
No announcement by December 31
33%
Kyle Diamantas 13%
Brett Giroir 8.2%
Sara Brenner 7.2%
Stephen Hahn 6.2%
$18,953 Vol.
$18,953 Vol.
Dec 31, 2026
Kyle Diamantas
$6,163 Vol.
25%
Stephen Hahn
$1,802 Vol.
6%
Brett Giroir
$3,007 Vol.
8%
Grace Graham
$4,151 Vol.
4%
Sara Brenner
$2,798 Vol.
7%
No announcement by December 31
$1,032 Vol.
33%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The FDA commissioner search remains unresolved following Marty Makary’s May 2026 resignation, leaving Kyle Diamantas as acting commissioner with a record of advancing food safety and nutrition priorities. White House vetting of finalists including Heidi Overton, Jeffrey Vacirca, and Stephen Ferrara continued into July 2026, yet no nomination has emerged by mid-August. This delay elevates the probability of no announcement before December 31 while sustaining support for Diamantas and lower odds for experienced figures such as Brett Giroir, Sara Brenner, Stephen Hahn, and Grace Graham. Senate confirmation dynamics, the preference for candidates with medical or regulatory backgrounds, and midterm-year timing all contribute to the tight distribution of implied probabilities among traders assessing the next permanent nominee.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Market Opened: May 12, 2026, 7:59 PM ET
Volume
$18,953End Date
Dec 31, 2026Market Opened
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The FDA commissioner search remains unresolved following Marty Makary’s May 2026 resignation, leaving Kyle Diamantas as acting commissioner with a record of advancing food safety and nutrition priorities. White House vetting of finalists including Heidi Overton, Jeffrey Vacirca, and Stephen Ferrara continued into July 2026, yet no nomination has emerged by mid-August. This delay elevates the probability of no announcement before December 31 while sustaining support for Diamantas and lower odds for experienced figures such as Brett Giroir, Sara Brenner, Stephen Hahn, and Grace Graham. Senate confirmation dynamics, the preference for candidates with medical or regulatory backgrounds, and midterm-year timing all contribute to the tight distribution of implied probabilities among traders assessing the next permanent nominee.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$18,953End Date
Dec 31, 2026Market Opened
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...The FDA commissioner search remains unresolved following Marty Makary’s May 2026 resignation, leaving Kyle Diamantas as acting commissioner with a record of advancing food safety and nutrition priorities. White House vetting of finalists including Heidi Overton, Jeffrey Vacirca, and Stephen Ferrara continued into July 2026, yet no nomination has emerged by mid-August. This delay elevates the probability of no announcement before December 31 while sustaining support for Diamantas and lower odds for experienced figures such as Brett Giroir, Sara Brenner, Stephen Hahn, and Grace Graham. Senate confirmation dynamics, the preference for candidates with medical or regulatory backgrounds, and midterm-year timing all contribute to the tight distribution of implied probabilities among traders assessing the next permanent nominee.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions